What is the rare cancer Maryam Moshiri is fighting?

A diagnosis made public

A BBC News presenter has made her cancer diagnosis public. Maryam Moshiri announced she is fighting a rare type of blood cancer. The condition is polycythaemia vera. Moshiri is 49 years old. She is a familiar anchor on the corporation's news channel, a face seen by millions of people delivering the day's breaking stories and political developments. Now she is the news. The announcement was made directly through the BBC's own health reporting, a deliberate choice by a journalist used to the careful management of public information.

Moshiri provided one clear reason for the disclosure. To raise awareness. She told the BBC she wanted the public to know about her condition, an illness that most people have never heard of before. Her account specified this was her motivation. It was a simple explanation. It was not something more. By using her considerable platform as a nationally recognised broadcaster, she has single handedly pushed a complex medical term out of obscurity and into the mainstream British press.

The decision completely transforms her public role. A person who reports on the difficult and often private experiences of other people is now sharing her own deeply personal story. This is a sharp reversal. The presenter who reads the autocue has become the subject of the copy, her private medical situation now an item for public discussion and analysis. For viewers accustomed to seeing her in the anchor's chair, this news reframes her familiar presence on screen. It adds a different context.

This was a calculated act of communication. It was not a leak. Moshiri revealed her diagnosis of polycythaemia vera, which is an incurable cancer, with the stated aim of informing the British public about what the disease is. There was no other agenda mentioned in her official communication with the BBC, only the explicit desire that more people should understand the reality of an illness that affects thousands. Her words now form the foundation of that new public awareness, an awareness that did not exist before she spoke.

A rare and incurable blood cancer

Polycythaemia vera is the medical name for the condition. It is a slow growing blood cancer. It is not common. The disease is currently known to affect around 15,000 people in the whole of Britain, a figure that situates it firmly in the category of rare illnesses and explains why it remains unfamiliar to most of the public. The diagnosis is life changing. It is also incurable. Doctors have no way to remove the disease entirely, meaning any treatment is focused on managing the symptoms and reducing the considerable risks that the condition creates over a patient's lifetime. Management is the only option. Not a cure.

The cancer's core mechanism is an overproduction of cells. The bone marrow produces far too many red blood cells. This is the root problem. This excess of cells floods the bloodstream, changing its consistency from a fluid that moves easily into a thicker, more viscous substance that places immense strain on the circulatory system. The clinical term for this is hyperviscosity. Blood flow slows down. The body’s ability to transport oxygen efficiently through its vast network of vessels becomes compromised, creating a dangerous internal environment that can lead to sudden medical emergencies. This is a quiet process. It has visible results.

Those results are serious. The main danger from the thickened blood is the formation of clots. They should not happen. These blockages, known as thrombi, can develop in veins or arteries, disrupting the normal flow of blood and leading to potentially fatal consequences depending on where they occur. The primary risks associated with polycythaemia vera are blood clots, heart attacks and strokes. A clot can break free and travel to the lungs, causing a pulmonary embolism, or it can form inside the critical arteries that supply the brain and heart with oxygenated blood. Constant medical supervision is required. The goal is to keep the blood thin enough to prevent these events from happening.

Fifteen thousand people. That is the estimated number of patients in the UK who live with this reality every day. This small patient population means polycythaemia vera exists in relative obscurity, unlike other major illnesses which are the subject of regular public health campaigns and widespread media coverage. The diagnosis has no public profile. Few recognise the name. The decision by a public figure like Maryam Moshiri to speak openly about her diagnosis introduces this complex medical term to an audience of millions, potentially changing the public understanding of a disease that has long remained in the shadows. This is why she spoke.

'Bleeding through her clothes'

Treatment is not simple. It can be primitive. Maryam Moshiri described one form of it as 'horrendous'. The 49 year old presenter gave a stark account of the physical cost of managing her condition, an experience which left her 'bleeding through her clothes'. This is the reality. The blood must come out. A primary method for treating polycythaemia vera is a procedure called venesection, a clinical term for the controlled, therapeutic removal of blood from the body. It sounds medieval. It works.

The process is mechanically simple, almost identical to giving blood, but its purpose is entirely different, designed not to help others but to save the patient from their own overproductive marrow. A needle is inserted into a vein. Around a pint of blood is drained away. This physically reduces the volume of red blood cells in the circulation, immediately thinning the blood and lowering the risk of a clot, a stroke, or a heart attack. The relief is temporary. The body keeps making more cells. Patients often need to repeat the procedure regularly, sometimes weekly or monthly, making it a constant and draining feature of their lives. It is a relentless cycle.

The experience Moshiri described points to the unvarnished difficulty of this management, where a routine medical necessity becomes an ordeal with distressing consequences. While venesection is the mechanical solution, there are also chemical ones. Doctors can prescribe medications. These drugs work to suppress the bone marrow itself, slowing down the internal factory that produces the excess red blood cells and offering a different kind of control over the disease. Often a combination of venesection and medication is used, a tailored strategy to keep the patient's blood viscosity within a safe range. This is not a cure. It is a long term strategy. A life sentence of treatment.

Despite the 'horrendous' nature of the interventions she has faced, Moshiri’s public statement also contained a clear eyed assessment of her situation. She said the treatment is 'better than dying'. This single phrase captures the stark choice confronting the fifteen thousand Britons who share her diagnosis. They endure the gruelling, the painful and the invasive because it is the only way to keep living with an illness that has no cure. It is a bargain made with biology.

Why this is classified as a cancer

Polycythaemia vera is a cancer. The word itself carries a unique weight, a gravity that can instantly reshape a person's life and their perception of the future. Yet this particular diagnosis does not align with the common image of the disease, the one fixed in the public mind by decades of health campaigns and dramatic portrayals. This is not a tumour. There is no lump. PV does not present as a solid mass that can be surgically removed or targeted with radiation in the way a breast or lung cancer might be. It is a disorder of the blood, a slow moving and invisible process deep within the bone marrow, making its classification as a cancer confusing for many patients when they first receive the news.

The classification is precise. It is a biological definition. It is a cancer because it involves the uncontrolled production of cells, a fundamental malfunction at the body’s most basic level. In a healthy person, the bone marrow is a highly regulated factory, manufacturing new blood cells only when the body signals that they are needed to replace old ones. With polycythaemia vera, this control system breaks down completely. The genetic machinery inside certain marrow cells becomes faulty, instructing them to proliferate without limit and without purpose, churning out a vast excess of red blood cells that the body does not need and cannot handle. It is this unregulated growth, this cellular rebellion against the body's own rules, that places PV firmly within the family of cancers, alongside leukaemias and lymphomas.

For the fifteen thousand people in Britain living with the condition, including the 49 year old presenter Maryam Moshiri, this label has profound consequences. It is a heavy burden. The word itself can provoke fear and anxiety, changing how a person views their own body and their prospects for a long life. It is not an easy thing to hear. But the designation is not only a source of distress. It is also a key. Classifying PV as a cancer is crucial for ensuring patients receive the correct level of medical attention and support, placing them on pathways to specialised haematology departments.

This formal classification provides a clear rationale for the lifelong monitoring patients require. It legitimises the seriousness of an invisible illness. The label also grants access to a wider network of resources, from the practical assistance offered by cancer charities to workplace protections and financial aid schemes designed for those with a cancer diagnosis. In this way, a word that brings immense psychological weight also provides a critical framework for survival.

When a newsreader becomes the news

A newsreader’s job is to report the news. It is not to be the news. For Maryam Moshiri, that has changed. The BBC presenter, whose work involves communicating events to the nation with clarity and detachment, has now turned the lens upon herself. This is a profound reversal. Her announcement places a personal and painful reality into the public domain, using the very platform from which she normally reports on the struggles of others. A career spent as a conduit for information is now being used to broadcast her own story, transforming her role from an observer of the world's events into a participant in a very public health narrative. She chose to do this. Moshiri told the BBC she wanted to raise awareness.

The effect is powerful. When a public figure, particularly one trusted to deliver daily facts, shares a diagnosis, it gives a human face to a complex medical condition. Polycythaemia vera was, for most people, an obscure term. A difficult word. Now, it is the illness being fought by the woman who reads the news. This act of public disclosure can demystify a rare disease, moving it from a clinical definition in a medical textbook to a tangible human experience that affects neighbours, colleagues and family members. It connects her personal battle with the fifteen thousand other people in Britain who are living with the same incurable blood cancer, suddenly giving their silent struggle a prominent national voice. It makes the abstract real.

This publicity can have direct, practical consequences beyond simply informing the public. A personal story, especially one involving a ‘horrendous’ treatment experience like the one Moshiri described, can break down the stigma and isolation that often accompany a serious diagnosis. People listen. The awareness she sought to create often translates into action, prompting individuals with persistent or unexplained symptoms to seek a medical opinion where they might otherwise have hesitated. Such announcements have historically driven spikes in public health enquiries. They encourage conversation. By sharing her vulnerability, a news anchor reinforces the very idea of a shared public health sphere, where one person’s story can serve as a catalyst for another’s diagnosis and support.

A future of management, not cure

The diagnosis is not a death sentence. It is a life sentence. For Maryam Moshiri, who is 49, polycythaemia vera is a condition to be managed for the rest of her life. This is the reality. It is the same reality for the other fifteen thousand people in Britain who live with this incurable blood cancer. While the disease itself is slow growing, the risks it carries are acute and immediate, including life threatening blood clots, heart attacks and strokes. The future becomes a continuous effort to prevent these outcomes, a sustained campaign of medical intervention that extends for decades. It is a future of management. Not of cure.

This management is a demanding, lifelong job. It is not a simple prescription. It is a regimen of constant vigilance that becomes woven into the fabric of daily existence, a routine dictated by the body’s rogue production of red blood cells. Patients face an endless cycle of hospital appointments for blood tests and consultations, often in specialised haematology units. They may undergo regular venesections, the process of removing blood which Moshiri herself described as a ‘horrendous’ ordeal. This is not a one time treatment but a recurring procedure, a physical reminder of the chronic nature of their condition. The psychological weight is immense. Life continues, but it continues with the quiet, persistent knowledge of the cancer within, a knowledge that reshapes how one plans, works and lives from the moment of diagnosis onwards.

Maryam Moshiri made her announcement on 6 September. Her story now belongs to the public. But thousands of others navigate this same path in private, managing the complex logistics of a chronic illness away from the cameras. Their fight is the same. It is a life recalibrated around the demands of the disease, a constant negotiation with a body that cannot be fully trusted. The objective of every treatment, from medication to blood removal, is to keep the blood thin enough to flow safely, to grant the patient as normal a life as possible for as long as possible. The prognosis for many is to live for decades. But it is a life lived under medical supervision, a marathon of endurance where the finish line is not a cure but the successful deferral of the cancer’s worst consequences. The goal is a long life. It is not an easy one.

Sources. BBC News Health: BBC News presenter reveals she has blood cancer. Independent UK: What is polycythaemia vera? The incurable cancer that BBC news presenter Maryam Moshiri is battling. Evening Standard: BBC News anchor Maryam Moshiri shares 'horrible' incurable cancer diagnosis - but says treatment 'better than dying'.

Analysis. Drafted with AI assistance from the sources listed above and reviewed by an editor before publication. Jnews links to the organisations it writes about.